Objectives: To systematically review available evidence and establish guidelines related to the risk of developing thrombosis and the management of small animals with antithrombotics.
INTRODUCTION
Thrombosis is commonly encountered in critically ill small animals [1] [2] [3] [4] [5] [6] and causes substantial morbidity and mortality. 3, [7] [8] [9] Thrombosis contributes to morbidity and mortality through promotion of inflammation [10] [11] [12] [13] and through direct end-organ damage. 14 Thrombosis complicates the management of multiple disease processes 15 and is the primary cause of various veterinary emergency room visits. 16 Furthermore, thrombi can propagate and may increase the propensity for additional clot formation and embolization. [17] [18] [19] The epidemiology of thrombosis in human medicine is well understood, [20] [21] [22] [23] [24] [25] [26] [27] and the substantial economic costs entailed in the management of thrombosis are also well documented. [28] [29] [30] Such data are not available in veterinary medicine. Although the burden of disease may be less in small animals than in people, it is likely still substantial. In the United States in 2017, there were approximately 96 million cats * and 90 million dogs, † and the US pet care segment of the veterinary services market was worth $13.5 billion. ‡ If thrombotic disorders account for even 0.01% of this spending, then client costs for the diagnosis and management of thrombotic complications in small animals amount to millions of US dollars annually.
In human medicine, multiple iterations of evidence-based guidelines for the management of venous [31] [32] [33] [34] [35] and arterial thrombosis have been published. 36, 37 These guidelines are based on a wealth of high-quality evidence resulting from large-scale randomized controlled trials. [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Although some of these guidelines may be applicable to small animals, it is clear that the underlying physiology, 50-53 the overall burden of disease, and the most frequently associated disease processes are substantially different between people and small animals. 1, 15 As such, there is a clear need for veterinary specific guidelines on the use of antithrombotics. [54] [55] [56] The available evidence from veterinary medicine, from animal models of human disease, and where necessary from human medicine relevant to the administration, monitoring, and discontinuation of antithrombotic medications in small animals was compiled to produce a series of evidence-based guidelines that were presented and discussed at both the European Veterinary Emergency and Critical Care (EVECC) Congress and the International Veterinary Emergency and Critical Care Symposium (IVECCS) in 2018. The draft guidelines were subsequently opened to community comment, revised as necessary, and edited for consistency prior to submission for publication.
In these guidelines and in the accompanying domain summary documents, we have used the terms antithrombotic and thromboprophylaxis to encompass antiplatelet agents and antiplatelet therapy and anticoagulants and anticoagulation. Owing to an overall paucity of evidence and limited clarity in the veterinary literature, we do not differentiate the use of these medications in patients with risk factors for thrombosis but without current thrombosis from those with existing thrombosis. Rather, we refer to patients at risk for thrombosis. LOEs were allocated as for the Reassessment Campaign on Veterinary Resuscitation process, 57 such that LOE 1 represented randomized controlled trials in dogs or cats; LOE 2 represented prospective clinical studies in dogs or cats with concurrent controls, but without randomization; LOE 3 represented experimental laboratory studies in dogs or cats; LOE 4 represented clinical retrospective studies in dogs or cats with both study and control groups from a previous period in time; LOE 5 represented case series and case reports in dogs or cat without a control group; and LOE 6 represented studies in humans. Within each LOE, the quality of the study was then subjectively assessed as Good, Fair, or Poor based on descriptors from the Centre for Evidence-Based Medicine. § It should be noted that because some aspects of these assessments were subjective, variation in the scores assigned to individual studies across domains is possible. In addition, while an LOE and quality score could be assigned to every study assessed, not every study was equivalently applicable to the PICO question at hand. Worksheet authors and domain chairs therefore made determinations as to the relevance of the study to the PICO question and hence some studies were classified as neutral to the PICO question, irrespective of their evidence level or quality. Some studies that did not directly address the PICO question regarding efficacy were included nonetheless, because they provided evidence for safety or adverse effects that was considered pertinent to prescribing practices.
MATERIALS AND METHODS

An
Following evidence assessment, worksheet authors were asked to digest and weigh the evidence, to discuss the results of their review, to summarize the body of evidence, and to draft guideline recommen- Domain chairs then reviewed all worksheets and suggested revisions, edits, and additional searches as required. Draft guidelines were reviewed and revised as deemed necessary by the domain chairs.
These draft guidelines were summarized and presented to the community at the 2018 EVECC Congress. Feedback provided by delegates at the EVECC Congress enabled and prompted some revision of the guidelines. These revised guidelines were then subjected to 3 rounds of a Delphi survey process [60] [61] [62] [63] to reach consensus on the content and formulation of the final draft of the guidelines. This Delphi process was conducted anonymously over a 3-week period via an online survey instrument ¶ and involved the committee chairs and all worksheet authors. Participants were given comprehensive instructions on the conduct of the Delphi survey prior to beginning. Following each iteration, collated collective feedback from the prior round and copies of both the previous and the revised versions of the guidelines were distributed to participants (Data S3). Below each guideline, the degree of consensus achieved is presented in addition to a short narrative statement describing the rationale and listing the supporting evidence assessments. Accompanying manuscripts in this edition of the Journal present the PICO questions, corresponding guidelines, discuss the relevant evidence in more detail, and highlight key knowledge gaps.
The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process provides guidance on quality of evidence rating and on the expression of strength of recommendations in systematic reviews, health technology assessments, and clinical practice guidelines. 64 Under the GRADE scheme, recommendations are characterized as strong or weak (conditional or discretionary) according to the supporting evidence quality and the balance between desirable and undesirable consequences of the alternative options. 65 The Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care guidelines adopt this 2-tier recommendation system and are formatted per the 2016 Surviving Sepsis Campaign. 66 Thus, strong recommendations in Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care are written as "We recommend…," whereas weak recommendations are in the format "We suggest…." [126] [127] [128] [129] and the presence of thrombi in tumors. [130] [131] [132] Hypercoagulability in dogs with neoplasia appears to be multifactorial. 98,127,129, b. We suggest that antithrombotic therapy be considered when an ischemic stroke is identified and a concurrent medical condition associated with a risk for thrombosis is present.
GUIDELINES
Delphi process: 12/13 panel members responding agreed (round 2).
One panel member felt that the guideline might be less applicable to patients with concurrent ischemic and hemorrhagic strokes.
Information provided by 3 studies (LOE 5, Fair) suggest that ischemic strokes are more likely the result of a hypercoagulable conditions than a risk factor for thrombosis themselves. [141] [142] [143] None of the dogs included in retrospective studies of PTE, arterial thromboembolism (ATE), portal vein, or splenic vein thrombosis had cerebrovascular disease. [79] [80] [81] 88, 102, 106, 107, 115, 116, 118 1.9 Heart disease (cats) a. Feline cardiomyopathy is strongly associated with a risk of ATE.
b. Cats with a history of ATE, left atrial (LA) dilation, spontaneous echocontrast, or reduced LA appendage flow velocity may be at particular risk.
c. We recommend antithrombotic therapy for cats with cardiomyopathy, particularly in those with the above risk factors.
One panel member felt this guideline should state "we strongly recommend."
Three studies (LOE 2-4, Good-Fair) strongly support the association of feline cardiomyopathy with ATE. [144] [145] [146] The cumulative risk of ATE at 1, 5, and 10 years was 3.5%, 9.5%, and 11.3%, respectively, in cats with hypertrophic cardiomyopathy or hypertrophic obstructive cardiomyopathy compared to 0.0%, 0.4%, and 0.7%, respectively, in apparently healthy cats (LOE 2, Good). 144 Five other studies (LOE 2-4, c. Dogs or cats with >1 disease/risk factor for thrombosis (eg, pancreatitis with sepsis).
Delphi process: 13/13 panel members responding agreed (round 2).
As discussed above, strong associations exist between thrombosis and IMHA and PLN in dogs and with cardiomyopathy in cats. Where the association is weaker, reference to human scoring systems and guidelines provides a rational approach to risk stratification. [154] [155] [156] It is likely that risk factors for thrombosis are cumulative. 154 The risk of bleeding versus the risk of thrombosis should be considered for each individual patient before deciding upon initiation or discontinuation of antithrombotics. Individual risk should account for the underlying condition(s), the inflammatory state of the animal, planned procedures, the likelihood the underlying condition can be resolved in a timely fashion, and the impact of medications such as glucocorticoids on thrombotic risk.
1.12
We define low/moderate risk for thrombosis as a. Dogs or cats with a single risk factor/disease.
b. Dogs or cats with known risk factor conditions that, with treatment, are likely to resolve in days to weeks.
See Section 1.11 for key supporting evidence.
Domain 2: Defining rational therapeutic use
Antiplatelet agents versus anticoagulants for VTE (dogs)
a. We suggest that anticoagulants may be more effective than antiplatelet agents for venous thromboembolism (VTE) prevention in dogs in general and in dirofilariasis specifically.
Delphi process: 14/14 panel members responding agreed (round 1).
Evidence from 1 study in dogs (LOE 3, Good) suggested that heparin was superior to aspirin for prevention of thrombus formation under venous shear. 157 An additional study (LOE 3, Good) evaluated thrombus formation in the low-shear setting of the pulmonary arterial system in dogs with experimentally induced dirofilariasis and demonstrated that neither aspirin or aspirin and dipyridamole protect against PTE in dirofilariasis. 158 
Antiplatelet agents versus anticoagulants for VTE (cats)
a. No evidence-based recommendations can be made regarding the use of antiplatelet agents for VTE in cats.
b. We suggest that anticoagulants rather than antiplatelet agents be used for the prevention of VTE in cats.
Two publications were identified (LOE 3, Good) suggesting that aspirin has limited, if any, efficacy for prevention of pulmonary thromboembolism due to dirofilariasis in cats. 159, 160 Evidence for efficacy of anticoagulants in VTE in cats is presented elsewhere (Sections 3.2.10, 3.2.12, 3.2.14, 3.3.8, 3.3.10, and 3.3.12).
2.3
Antiplatelet agents versus anticoagulants for ATE (dogs) a. We suggest that antiplatelet agents may be more effective than anticoagulants for the prevention of ATE in dogs.
b. We suggest that anticoagulants may also be effective for prevention of ATE in dogs.
Delphi process: 12/14 panel members responding agreed (round 1).
One panel member felt the rarity of ATE in dogs limited the evidence base and hence increased the risk associated with this guideline. One panel member felt that thrombosis in canine coronary vessels might be distinct from thrombosis in the aorta.
Three studies (all LOE 3, Good) suggested that anticoagulants were inferior to antiplatelet agents in the setting of provoked arterial thrombosis. [161] [162] [163] Multiple studies (19 LOE 3, Good; 1 LOE 3, Fair) also suggest efficacy of anticoagulants for arterial thrombosis in dogs, however. [164] [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] 
Antiplatelet agents versus anticoagulants for ATE (cats)
a. We recommend that antiplatelet agents be used for the prevention of ATE in cats. 
Clopidogrel versus aspirin (cats)
a. We recommend that clopidogrel be used instead of aspirin in cats at risk for ATE.
b. There is no evidence on which to base recommendations regarding the use of aspirin or clopidogrel in cats at risk for VTE.
One prospective study in cats (LOE 1, Good) provides evidence that clopidogrel is superior to aspirin for thromboprophylaxis in cats with previous aortic thromboembolic events. 188 
New antiplatelet agents versus clopidogrel or aspirin (dogs)
a. There is insufficient evidence to make recommendations regarding the use of new antiplatelet agents versus clopidogrel or aspirin in dogs.
b. We suggest that both abciximab and ticagrelor appear safe and may be efficacious antiplatelet agents in dogs.
No clinical studies evaluating novel antiplatelet agents in dogs were identified. Four experimental studies (all LOE 3, Fair) suggest efficacy for novel antiplatelet agents in dogs, [189] [190] [191] [192] but of these, only ticagrelor and abciximab are commercially available.
New antiplatelet agents versus clopidogrel or aspirin (cats)
a. There is insufficient evidence to make recommendations regarding the use of new antiplatelet agents versus clopidogrel or aspirin in cats.
b. We suggest that abciximab appears safe and may be efficacious as an antiplatelet agent in cats.
No clinical studies evaluating novel antiplatelet agents in cats were identified. In 1 experimental study (LOE 3, Fair), abciximab demonstrated efficacy in a feline model of arterial injury. 193 
UFH versus LMWH (dogs)
a. There is insufficient evidence to make strong recommendations regarding the use of UFH versus LMWH in dogs.
b. We suggest that LMWH may be used in preference to UFH because of the positive safety profile of LMWH and more reliable bioavailability of the LMWH products compared to UFH. No studies directly addressed the relevant PICO question.
Two pharmacokinetic-pharmacodynamic (PK-PD) studies (LOE 3, Good) 211, 212 suggest that rivaroxaban and apixaban are well tolerated in cats and have reproducible PK-PD parameters.
Direct Xa inhibitors versus LMWH (dogs)
a. There is insufficient evidence to make strong recommendations regarding the use of the direct Xa inhibitors versus LMWH in dogs.
b. We suggest that use of either the direct Xa inhibitors or LMWH in dogs is reasonable.
No prospective randomized clinical studies were identified comparing these 2 drug classes in dogs. One experimental study (LOE 3, Good) demonstrated that a direct Xa inhibitor had equivalent efficacy to enoxaparin for prevention of arterial and venous thrombosis. 181 Seven studies (all LOE 3, Good-Fair) of direct Xa inhibitors suggest these drugs are safe, orally active, and have reliable and reproducible PK-PD parameters in dogs. 208 No studies directly addressed the relevant PICO question. Two PK-PD studies (both LOE 3, Good) 211, 212 suggest that rivaroxaban and apixaban are well tolerated in cats and have reproducible PK-PD parameters.
UFH versus warfarin and LMWH versus warfarin (dogs and cats)
a. There is insufficient evidence to make strong recommendations regarding the efficacy of heparin products versus warfarin in dogs or cats.
b.
We suggest that UFH or LMWH be used in preference to warfarin (see other recommendations regarding the choice between UFH
and LMWH).
Delphi process: 12/12 panel members responding agreed (round 3).
There is insufficient evidence comparing UFH or LMWH with warfarin in dogs or cats at risk of thrombosis. There is evidence supporting the use of the drug classes individually, which suggests their use may be preferable in certain diseases of dogs or cats at risk for thrombosis.
The efficacy of UFH, LMWHs, and warfarin are discussed elsewhere.
2.16
Direct 
2.18
Combination anticoagulant and antiplatelet therapy for VTE (cats) a. There is insufficient evidence to make strong recommendations regarding combination anticoagulant and antiplatelet agent therapy in cats.
b. We suggest that combination therapy may be considered where there is a high risk of thrombosis and the risk of clot formation is felt to outweigh the increased risk of bleeding resulting from combination therapy.
Delphi
No studies directly address the relevant PICO question in cats. The guideline recommendation is primarily based on data reviewed in this and other domains and represent the current practice of the committee.
2.19
Combination antiplatelet and anticoagulant therapy for ATE (dogs) a. There is insufficient evidence to make strong recommendations for or against the use of combination antiplatelet and anticoagulant therapy in dogs at risk for ATE.
b. We suggest that administration of clopidogrel or aspirin with LMWH may be considered in dogs at risk for ATE. 
Warfarin (dogs)
a. We suggest that warfarin should not be used in dogs because it inconsistently improves outcomes and is commonly associated with bleeding complications.
Delphi process: 11/14 panel members responding agreed (round 1).
One panel member felt the guideline should specify "for thrombo-
prophylaxis." One panel member felt warfarin could still be considered with some patients and compliant clients. One panel member dissented but an alternative suggestion was not made.
In dogs, 10 studies (LOE 1-5, Good-Poor) suggest efficacy of warfarin in vivo in dogs or using in vitro tests. 4 Delphi process: 13/14 panel members responding agreed (round 1).
One panel member dissented but an alternative suggestion was not made.
Two studies (both LOE 3, Fair-Poor) suggest warfarin has some efficacy in cats. 280, 281 Three studies (LOE 3-5, Good-Poor) suggest a lack of efficacy for warfarin in the cat. 282-284
Unfractionated heparin (dogs)
a. UFH can be effectively administered by the IV or SC routes in dogs.
b. Optimal UFH dose likely varies in individual dogs to maximize
antithrombotic effects and minimize hemorrhagic complications.
c. We suggest an initial IV dosing scheme of 100 U/kg bolus, then 480-900 U/kg every 24 hours (20-37.5 U/kg every hour) constant rate infusion in dogs.
d. We suggest an initial SC dosage of UFH of 150-300 U/kg every 6 hours in dogs.
e. We recommend that UFH is not administered by inhalation or PO in dogs.
Eight studies (LOE 1-4, Good-Fair) suggest UFH is efficacious in dogs. 8, [285] [286] [287] [288] [289] The optimal dosing scheme is unestablished, however, and a consistent, effective, and safe fixed UFH dose likely does not exist. Individual dose adjustment based on anti-Xa monitoring appears effective in dogs (LOE 1, Good). 286 Inhaled UFH does not appear effective in dogs (LOE 3, Fair). 290 
Unfractionated heparin (cats)
a. Only a SC route of administration of UFH has been investigated in cats.
b. We suggest an initial SC dosage of UFH of 250 U/kg every 6 hours in cats.
Only 1 study (LOE 3, Fair) was identified investigating the effect of UFH 250 U/kg every 6 hours in cats. 202 There are insufficient data to suggest superiority or inferiority of UFH compared to other regimens in cats.
Dalteparin (dogs)
a. We suggest an initial SC dosage of 100-175 U/kg every 8 hours in dogs.
b. Minor bleeding may be noted at the doses reported above, but serious bleeding is unlikely.
Four studies (LOE 3-5, Fair-Poor) suggest some of efficacy for dalteparin in dogs. 287, [291] [292] [293] Six studies (LOE 3-5, Fair-Poor) report usage of dalteparin in cats but were considered neutral to the relevant PICO question. 184, 199, 200, 202, 203, 244 A dosing scheme of 75-150 U/kg administered subcutaneously every 6 hours may be reasonable, 199, 202 but the relationship between anti-Xa activity and clinical efficacy in cats has not been firmly established. Bleeding complications, usually self-limiting and minor in nature, may occur with a variety of dosing schemes in cats. 184, 199, 202 
Enoxaparin (dogs)
a. We suggest enoxaparin at a dosage of 0.8 mg/kg SC every 6 hours is safe and well tolerated in dogs.
b. This dose may not achieve anti-Xa levels considered to be therapeutic in people in all breeds of dog.
c. Only minor bleeding complications have been reported in associa-
tion with enoxaparin use in dogs.
Five studies (LOE 3-5, Good-Poor) suggest enoxaparin is effective in dogs, 287, [294] [295] [296] [297] with 0.8 mg/kg SC every 6 hours the most commonly reported protocol. [294] [295] [296] There is no evidence suggesting that enoxaparin is superior to other drugs or protocols and doubt has been raised about the uniformity of enoxaparin's activity at 0.8 mg/kg SC every 6 hours across all dog breeds. 298 
Enoxaparin (cats)
a. We suggest enoxaparin at a dosage of 0.75-1 mg/kg SC every 6 12 hours should be considered in cats with a risk of VTE.
b. We suggest enoxaparin be administered every 6 hours to reduce interindividual variation in peak anti-Xa activity.
One panel member felt that every 6 hours and every 12 hours dosing were not equivalent, indicating comparisons of every 6 hours with every 12 hours dosing using clinically relevant endpoints are lacking.
Three studies (all LOE 3, Fair) suggest efficacy for enoxaparin in healthy cats. 198, 201, 202 The most commonly used protocol is 0. The general applicability of these data is uncertain. Numerous studies have assessed the effect of aspirin on platelet function in healthy cats, using a variety of in vitro methods. 241, 245, 264, 300, 301 Results are variable, which may reflect methodologic differences, but overall, they suggest aspirin has limited antiplatelet efficacy in cats, particularly against potent platelet agonists.
Warfarin
a. We suggest that warfarin should not be used in dogs or in cats. b. An anti-Xa target of 0.35-0.7U/mL is recommended in dogs to minimize thrombosis risk and improve outcome, although minor hemorrhage may still occur.
c. There is insufficient evidence to make a strong recommendation for a specific anti-Xa target in cats.
d. We suggest an anti-Xa target of 0.35-0.7U/mL is reasonable in cats until more evidence is available.
Data from a single randomized controlled trial (LOE 1, Fair) suggest that there is an outcome benefit from adjusting UFH doses based upon therapeutic monitoring. 286 That study and an experimental study (LOE 3, Fair) support the use of an anti-Xa activity range of 0.35-0.7 IU/mL. 287 The Helmond et al study 286 and a second prospective study (LOE 2, Fair) indicate that anti-Xa activity is the criterion (gold) standard for UFH monitoring. b. We suggest adjusting therapy in dogs, targeting anti-Xa levels of 0.5-1.0U/mL 2-4 hours after dose can be considered.
Four experimental studies in dogs (LOE 3, Good-Fair) addressed the PICO question, but provide limited evidence relevant to clinical practice. 181, 194, 196, 308 Various monitoring tests for LMWH in dogs including anti-Xa activity, PT, activated partial thromboplastin time, thrombin time, activated clotting time, thromboelastography, and the Sonoclot assay have been evaluated. 181, 194, 196, 288, 292, 308, 309 The antiXa assay appears to be the most sensitive test of the anticoagu- b. In patients at low to moderate risk for thrombosis, consideration may be given for discontinuation of anticoagulation prior to invasive procedures.
The risk for bleeding must be balanced with the risk for thrombosis. In patients that require invasive procedures (eg, surgery, biopsy), this balance is particularly acute and will depend on the underlying risk factors for thrombosis and hemorrhage as well as the type of procedure. In procedures where hemorrhage may be catastrophic (eg, neurosurgery) or unable to be easily controlled (eg, percutaneous renal biopsy), discontinuation or alteration of therapy is prudent. For lessinvasive procedures (eg, dental extraction and truncal mass removal), or those where hemorrhage may be addressed through tamponade (eg, surgery on a peripheral limb), anticoagulant therapy may continue through the procedure if there is a high risk of thrombosis without anticoagulation. These patients may also be switched to other medications with favorable pharmacokinetics for the periprocedural period. Consideration for the risk of rebound hypercoagulability should be given when planning complete or temporary cessation of therapy.
5.2
Antiplatelet agent discontinuation 5-7 days prior to an elective procedure versus no discontinuation (high risk) a. We recommend that antiplatelet therapy with a single antiplatelet agent should be continued.
b. We recommend discontinuing 1 agent if animals are receiving dual antiplatelet therapy.
c. We suggest that these patients are at increased risk of bleeding and that close attention be paid to surgical hemostasis.
No veterinary studies specifically addressed the relevant PICO question and hence multiple studies from human medicine (LOE 6, Fair) were extrapolated to generate this guideline. [314] [315] [316] [317] [318] [319] [320] [321] [322] [323] [324] [325] [326] [327] [328] The guideline represents a balance of the increased risk of thrombosis associated with drug discontinuation in patients with high-risk conditions 329 or where multiple risk factors exist compared to the perceived lower risk of surgical hemorrhage that may result from ongoing platelet inhibition of hemorrhage. 324, 325, 330 In addition, dual antiplatelet therapy with aspirin and clopidogrel can result in significantly more hemorrhage compared with antiplatelet monotherapy. 331, 332 
5.3
Antiplatelet agent discontinuation 5-7 days prior to an elective procedure versus no discontinuation (low/moderate risk) a. We recommend that antiplatelet agents should be discontinued prior to the planned procedure.
No veterinary studies specifically addressed the relevant PICO question and hence multiple studies from human medicine (LOE 6, Fair) were extrapolated to generate this guideline. [314] [315] [316] [317] [318] [319] [320] [321] [322] [323] [324] [325] [326] [327] [328] The guideline represents a balance of the perceived low risk of thrombosis associated with drug discontinuation in this patient population compared to the risk of perioperative bleeding.
5.4
UFH/LMWH discontinuation 24 hours prior to an elective procedure versus no discontinuation (high risk) a. We recommend that heparin therapy should not be discontinued.
b. We recommend that surgery be planned to occur at nadir of anticoagulant effect (approximately 6-8 hours after prior dose if given by subcutaneous injection).
No veterinary studies specifically addressed the relevant PICO question and hence multiple studies from human medicine (LOE 6, Good) were extrapolated to generate this guideline. [314] [315] [316] [317] [318] [319] [320] [321] [322] [323] [324] [325] [326] [327] [328] Patients at high risk of thrombosis are considered more likely to suffer consequences from thrombosis following discontinuation of heparin therapy than they are to suffer morbidity or mortality from procedure related hemorrhage. 333 Timing surgery to occur around the nadir of anticoagulant effect 334 coupled with scrupulous surgical hemostasis may mitigate the bleeding risk.
5.5
UFH/LMWH discontinuation 24 hours prior to an elective procedure versus no discontinuation (low/moderate risk) a. We recommend that consideration may be given to taper (UFH) or stop (LMWH) therapy prior to a procedure.
No veterinary studies specifically addressed the relevant PICO question. Evidence summary is as given in Section 5.5. In patients at low to moderate risk of thromboembolic disease, tapering or discontinuing heparin therapy may limit hemorrhage during procedures without significantly increasing the risk of thrombosis.
5.6
Antiplatelet agent discontinuation 5-7 days prior to surgery versus 24 hours (high risk) a. We recommend against withdrawing antiplatelet agents within 5 days of a procedure.
Four veterinary studies (LOE 3, Fair) 257,260,300,335 and 3 from human medicine (LOE 6, Good) [336] [337] [338] provided evidence for this guideline. In patients receiving irreversible antiplatelet agents, a 24-hour withdrawal time is unlikely to be different than not discontinuing the agent at all in patients at high risk for thrombosis 339, 340 and hence this guideline reflects as given in Section 5.2.
5.7
Antiplatelet agent discontinuation 5-7 days prior to surgery versus 24 hours (low/moderate risk) a. We recommend that antiplatelet agents be discontinued within 5 days of a procedure.
Four veterinary studies (LOE3, Fair) 257,260,300,335 and 3 from human medicine (LOE 6, Good) [336] [337] [338] provided evidence for this guideline.
Platelet lifespans are 7-9 days in people, 341 6.0 ±1.1 days in dogs, 342 and possibly shorter in cats. 343 However, platelet function may be acceptable to provide adequate surgical hemostasis prior to 5-7 days following cessation of medications, as functional platelets are introduced into the bloodstream on a continuous basis. In patients receiving irreversible antiplatelet agents, but with a low risk of thrombosis, progress toward a return of normal platelet function may be achieved prior to surgery by drug discontinuation and hence this guideline reflects 5.3 above.
5.8
Restarting antithrombotic therapy 24 hours post-surgery versus 3-5 days (high risk patient) a. We recommend that in patients at high risk, antithrombotic therapy should be restarted as soon as possible after surgery provided there is no evidence of ongoing bleeding.
5.9
Restarting antithrombotic therapy 24 hours postsurgery versus 3-5 days (low/moderate risk patient) a. No evidence-based recommendation can be made for patients at low/moderate risk.
b. We suggest that in patients at low/moderate risk, antithrombotic therapy be restarted once there is no evidence of ongoing bleeding.
5.10
Restarting antithrombotic therapy 24 hours postsurgery versus 3-5 days (patients that develop thrombosis) a. We recommend that antithrombotic therapy should be initiated immediately in patients that develop thrombosis in the postoperative period.
Five studies in human medicine (LOE 6, Good-Fair) provided evidence for guideline (a) in Section 5.10, which is based on an assessment of the likelihood of thrombosis compared to bleeding. 273, 344 Highrisk patients are more likely to be harmed by delays in administration of thromboprophylaxis than by mild postoperative bleeding. [345] [346] [347] There was insufficient evidence to make a recommendation regarding low-risk patients, but the panel has provided a consensus recommendation for guidance. One veterinary study (LOE 5, Good) supports prompt initiation of thromboprophylaxis in patients that develop thrombosis postoperatively. 274 
5.11
Discontinuation of antithrombotic therapy in patients where an in situ arterial blood clot is no longer identifiable a. We recommend that if the underlying causative conditions have resolved, antithrombotic therapy should be discontinued following thrombus resolution.
b. In patients with unknown underlying conditions or where these conditions cannot be cured or resolved, we recommend antithrombotic therapy should be continued indefinitely.
Evidence from 2 veterinary studies (LOE 1-5, Good) suggests that patients at high risk of arterial thrombosis may have recurrent thrombi despite antithrombotic medications. 82, 188 Several studies (LOE 1-3, Good-Poor) suggest that patients with a noncurable predisposing condition should not have therapy discontinued 119, 207, 348 and discontinuation is not recommended in such patients. Cessation of antithrombotic therapy, upon resolution of thrombosis, when the underlying cause was resolved, is supported by 3 case reports and a case series (LOE 4-5, Poor). 117, 274, 349, 350 
5.12
Discontinuation of antithrombotic therapy in patients where an in situ venous blood clot is no longer identifiable a. We recommend that if the underlying causative conditions have resolved, that antithrombotic therapy should be discontinued following thrombus resolution.
c. In patients with a low or moderate risk of thrombosis, we suggest that the risk of hemorrhage and the ability of the animal to tolerate antithrombotic therapy should be weighed against the risk of recurrence of the prothrombotic condition.
One panel member felt it was not clear that dogs receiving immunosuppressive corticosteroids for a condition such as IMHA that was resolving would require indefinite antithrombotics.
There are few quality studies assessing the long-term treatment of venous thrombi in veterinary patients. The available evidence is composed of case series (LOE 4, Good-Fair) and single case reports (LOE 5, Fair) and supports discontinuation of antithrombotics, upon resolution of the thrombus, when the underlying cause could be eliminated or had resolved. 14, 117, 244, 351, 352 In humans, studies (LOE 6, Good-Fair) support discontinuation of anticoagulation in patients with risk factors for thrombosis that can be resolved or removed. 353 No relevant veterinary studies were identified and hence 3 studies from human medicine (LOE 6, Poor) were extrapolated to generate this guideline. [369] [370] [371] Overall, there is insufficient evidence to confirm or refute a rebound effect following discontinuation of the direct Xa inhibitors. Several human case reports describe thrombotic events following discontinuation of rivaroxaban. [369] [370] [371] There are no data in dogs or cats on rivaroxaban withdrawal to provide guidance. Until more data are available, the panel suggests weaning of these therapies is reasonable.
CONCLUSIONS
These guidelines on the indications for, and prescribing, monitoring 
